Document Detail

Do angiotensin receptor blockers protect against Alzheimer's disease?
MedLine Citation:
PMID:  23532556     Owner:  NLM     Status:  MEDLINE    
Because growing evidence suggests that angiotensin II receptor blockers (ARBs) effectively inhibit oxidative stress, amyloid beta protein (Aβ) metabolism, and tau phosphorylation in animal brains, ARBs are considered to be a potential candidate for the treatment of Alzheimer's disease (AD). Consistent with such basic studies, two recent observational studies and a small prospective, randomized, open-label trial have shown the effectiveness of ARBs in preventing AD and/or slowing its progression. Nonetheless, large clinical trials have not shown their effectiveness, but their results are debatable because of short follow-up durations and heterogeneity of the cognition assessments used in the studies. Because a recent analysis of the Honolulu-Asia Aging study showed that abnormalities of the serum Aβ level begin approximately 15 years before the diagnosis of AD, long-term clinical trials assessing dementia as a primary endpoint with sensitive measurements of cognition and brain imaging techniques will clarify the effectiveness of ARBs in AD treatment.
Hitomi Kurinami; Munehisa Shimamura; Naoyuki Sato; Hironori Nakagami; Ryuichi Morishita
Related Documents :
11226726 - The clinical course of childhood and adolescent adrenoleukodystrophy before and after l...
9698976 - The relationship between pre-, during-, post-treatment factors, and adolescent substanc...
23510566 - Predictors of the disappearance of triad symptoms in patients with idiopathic normal pr...
23116976 - History of depression prior to alzheimer's disease and vascular dementia verified post-...
23708466 - Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents ...
24276036 - Chronic fatigue in long-term survivors of childhood lymphomas and leukemia: persistence...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs & aging     Volume:  30     ISSN:  1170-229X     ISO Abbreviation:  Drugs Aging     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-05-24     Completed Date:  2013-10-31     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  9102074     Medline TA:  Drugs Aging     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  367-72     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alzheimer Disease / prevention & control*
Amyloid beta-Peptides / metabolism
Angiotensin Receptor Antagonists / therapeutic use*
Benzimidazoles / therapeutic use
Benzoates / therapeutic use
Cerebrovascular Circulation / drug effects
Clinical Trials as Topic
Cognition / drug effects
Disease Progression
Oxidative Stress
Reg. No./Substance:
0/Amyloid beta-Peptides; 0/Angiotensin Receptor Antagonists; 0/Benzimidazoles; 0/Benzoates; U5SYW473RQ/telmisartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pill Burden in Hypertensive Patients Treated with Single-Pill Combination Therapy - An Observational...
Next Document:  Cabazitaxel: A Guide to Its Use in Hormone-Refractory Metastatic Prostate Cancer.